An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

Back to Search
Print
Bookmark Trial

NCT02907619

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
David Geffen School of Medicine at UCLA/UCLA Neorology
Los Angeles, California, 90095, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Duchenne Muscular Dystrophy
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6-18 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Subjects with Duchenne muscular dystrophy who enrolled and completed study B5161002.

2. Signed and dated informed consent document (ICD) indicating that the subject's parent or legal guardian/caregiver has been informed of all pertinent aspects of the study.

3. Subjects and their legal guardians/caregivers who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

4. Subject have;

1. Adequate hepatic function on screening laboratory assessments

2. GLDH less than 20 units/liter (2 x upper limit of normal [ULN])

3. Iron content estimate on the liver MRI within the normal range.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Unwilling or unable (eg, metal implants) to undergo examination with closed MRI.


2. All male subjects who are able to father children and are sexually active and at risk
for impregnating a female partner, who are unwilling or unable to use a highly
effective method of contraception. In addition, all sexually active male subjects who
are unwilling or unable to prevent potential transfer of and exposure to drug through
semen to their partners by using a condom consistently and correctly. .


3. Subjects who are investigational site staff members directly involved in the conduct
of the study and their family members, site staff members otherwise supervised by the
Investigator, or subjects who are related to Pfizer employees directly involved in the
conduct of the study.


4. Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation.


5. Participation in other studies involving investigational drug(s), with the exception
of B5161002.


6. History of allergic or anaphylactic reaction to a therapeutic or diagnostic protein or
additives of this investigational product.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Duchenne Muscular DystrophyA Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy
NCT02310763
  1. Los Angeles, California
  2. Los Angeles, California
  3. Los Angeles, California
  4. Sacramento, California
  5. Aurora, Colorado
  6. Tampa, Florida
  7. Chicago, Illinois
  8. Iowa City, Iowa
  9. Fairway, Kansas
  10. Fairway, Kansas
  11. Kansas City, Kansas
  12. Kansas City, Kansas
  13. Baltimore, Maryland
  14. Baltimore, Maryland
  15. Baltimore, Maryland
  16. Baltimore, Maryland
  17. Boston, Massachusetts
  18. Minneapolis, Minnesota
  19. Saint Louis, Missouri
  20. Durham, North Carolina
  21. Durham, North Carolina
  22. Cincinnati, Ohio
  23. Philadelphia, Pennsylvania
  24. Pittsburgh, Pennsylvania
  25. Salt Lake City, Utah
  26. Salt Lake City, Utah
  27. Salt Lake City, Utah
  28. Salt Lake City, Utah
  29. Salt Lake City, Utah
  30. Salt Lake City, Utah
  31. South Brisbane, Queensland
  32. Sofia,
  33. Sofia,
  34. Sofia,
  35. Sofia,
  36. Sofia,
  37. Calgary, Alberta
  38. Vancouver, British Columbia
  39. London, Ontario
  40. Montreal, Quebec
  41. Genova,
  42. Genova,
  43. Genova,
  44. Genova,
  45. Genova,
  46. Rome,
  47. Rome,
  48. Rome,
  49. Rome,
  50. Rome,
  51. Rome,
  52. Hyogo,
  53. Tokyo,
  54. Warszawa,
  55. Warszawa,
  56. Warszawa,
  57. Warszawa,
  58. Warszawa,
  59. Warszawa,
  60. Liverpool,
  61. Liverpool,
  62. London,
  63. London,
  64. Newcastle upon Tyne,
  65. Newcastle upon Tyne,
  66. Newcastle-upon-Tyne,
Male
6 Years+
years
MULTIPLE SITES
Duchenne Muscular DystrophyA Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy
NCT03760029
  1. Fuzhou, Fujian
  2. Beijing,
  3. Chongqing, Chongqing
  4. Beijing,
  5. Shanghai,
  6. Shanghai,
  7. Shanghai,
Male
0+
years
MULTIPLE SITES
Duchenne Muscular DystrophyA Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy
NCT03362502
  1. Durham, North Carolina
  2. Los Angeles, California
  3. Los Angeles, California
  4. Los Angeles, California
  5. Los Angeles, California
  6. Los Angeles, California
  7. Los Angeles, California
  8. Los Angeles, California
  9. Durham, North Carolina
  10. Durham, North Carolina
  11. Durham, North Carolina
  12. Durham, North Carolina
  13. Durham, North Carolina
  14. Salt Lake City, Utah
  15. Salt Lake City, Utah
  16. Salt Lake City, Utah
  17. Salt Lake City, Utah
  18. Salt Lake City, Utah
  19. Salt Lake City, Utah
  20. Salt Lake City, Utah
Male
4 Years+
years
MULTIPLE SITES
Duchenne Muscular DystrophyA Phase 3 Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy
NCT04281485
Male
4 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy
Official Title  ICMJE A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF PF-06252616 IN BOYS WITH DUCHENNE MUSCULAR DYSTROPHY
Brief Summary This study is an open-label extension to protocol B5161002 and will provide an assessment of the long term safety, efficacy, pharmacodynamics and pharmacokinetics of intravenous dosing of PF 06252616 in boys with Duchenne muscular dystrophy. Approximately 105 eligible subjects will be assigned to receive a monthly individualized maximum tolerated dose based on their tolerability profile/data from B5161002. This study will not contain a placebo comparator. Subjects will undergo safety evaluations (Laboratory, cardiac monitoring, physical exams, x-ray, MRI), functional capacity evaluations (4 stair climb, range of motion, strength testing, Northstar Ambulatory Assessment, upper limb functional testing, six minute walk test and pulmonary function tests) and pharmacokinetic testing.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Duchenne Muscular Dystrophy
Intervention  ICMJE Biological: PF-06252616
Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
Study Arms  ICMJE Experimental: PF-06252616
Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
Intervention: Biological: PF-06252616
Publications * Wagner KR, Abdel-Hamid HZ, Mah JK, Campbell C, Guglieri M, Muntoni F, Takeshima Y, McDonald CM, Kostera-Pruszczyk A, Karachunski P, Butterfield RJ, Mercuri E, Fiorillo C, Bertini ES, Tian C, Statland J, Sadosky AB, Purohit VS, Sherlock SP, Palmer JP, Binks M, Charnas L, Marraffino S, Wong BL. Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscul Disord. 2020 Jun;30(6):492-502. doi: 10.1016/j.nmd.2020.05.002. Epub 2020 May 19.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: May 8, 2019)		59
Original Estimated Enrollment  ICMJE
 (submitted: September 14, 2016)		105
Actual Study Completion Date  ICMJE November 22, 2018
Actual Primary Completion Date November 22, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subjects with Duchenne muscular dystrophy who enrolled and completed study B5161002.
  2. Signed and dated informed consent document (ICD) indicating that the subject's parent or legal guardian/caregiver has been informed of all pertinent aspects of the study.
  3. Subjects and their legal guardians/caregivers who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

  4. Subject have;

    1. Adequate hepatic function on screening laboratory assessments
    2. GLDH less than 20 units/liter (2 x upper limit of normal [ULN])
    3. Iron content estimate on the liver MRI within the normal range.

Exclusion Criteria:

  1. Unwilling or unable (eg, metal implants) to undergo examination with closed MRI.
  2. All male subjects who are able to father children and are sexually active and at risk for impregnating a female partner, who are unwilling or unable to use a highly effective method of contraception. In addition, all sexually active male subjects who are unwilling or unable to prevent potential transfer of and exposure to drug through semen to their partners by using a condom consistently and correctly. .
  3. Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or subjects who are related to Pfizer employees directly involved in the conduct of the study.
  4. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation.
  5. Participation in other studies involving investigational drug(s), with the exception of B5161002.
  6. History of allergic or anaphylactic reaction to a therapeutic or diagnostic protein or additives of this investigational product.
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Gender Based Eligibility:Yes
Ages  ICMJE 6 Years to 18 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   Italy,   Japan,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02907619
Other Study ID Numbers  ICMJE B5161004
2016-001615-21 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP